bicyclo<2.2.2>oct-1-yl fluoride | 20277-22-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机氟化物
• 英文名称: bicyclo<2.2.2>oct-1-yl fluoride
• 英文别名: 1-fluorobicyclo<2.2.2>octane；1-Fluor-bicyclo<2.2.2>octan；1-Fluorbicyclo<2.2.2>octan；1-Fluorobicyclo[2.2.2]octane
• CAS: 20277-22-9
• 化学式: C₈H₁₃F
• 分子量: 128.19
• InChiKey: HAQDPSRBYOWAEI-UHFFFAOYSA-N

物化性质

• 熔点：
  182-184 °C
• 沸点：
  142.5±9.0 °C(Predicted)
• 密度：
  0.98±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-碘双环[2.2.2]辛烷 在 二氟代氙 作用下， 以 二氯甲烷 为溶剂， 以88%的产率得到bicyclo<2.2.2>oct-1-yl fluoride
  参考文献：
  名称：

  Synthesis of bridgehead fluorides by fluorodeiodination

  摘要：

  Fluorodeiodination is found to be an attractive procedure for the synthesis of bridgehead fluorides. Thus, treatment of the corresponding iodide with xenon difluoride in dichloromethane at ambient temperature generally leads to high yields of the fluoride. Evidence suggests the intermediacy of the bridgehead cation in this reaction, and accordingly the substrates which are unfavorably disposed to fluorodeiodination are the bicyclo[n.1.1]alkyl iodides. In this context the isolation of a small quantity of methyl 4-fluorobicyclo[2.1.1]hexane-1-carboxylate (46, R = COOMe) is significant because it represents the first occasion on which the elusive 1-bicyclo[2.1.1]hexyl cation has been trapped. We have also demonstrated that synthesis of the iodides themselves can be accomplished efficiently both by Barton halodecarboxylation and by treatment of the carboxylic acid with lead tetraacetate and iodine.

  DOI：

  10.1021/jo00036a018

文献信息

• [EN] COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION DE CD73 ET LEURS INDICATIONS
  申请人：PLEXXIKON INC

  公开号：WO2021216898A1

  公开（公告）日：2021-10-28

  Disclosed are compounds of Formula (I): or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R1, R2, R3, A, E, L, and G are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  披露了公式(I)的化合物：或其药用盐、溶剂化物、互变异构体、立体异构体或氘代类似物，其中R1、R2、R3、A、E、L和G如本公开的任何实施方案所述；其组合物；及其用途。
• [EN] COMPOUNDS AND METHODS FOR IDO AND TDO MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS DE MODULATION D'IDO ET DE TDO, ET INDICATIONS POUR CEUX-CI
  申请人：PLEXXIKON INC

  公开号：WO2019183145A1

  公开（公告）日：2019-09-26

  Disclosed are compounds of Formula (I) and (Ia) or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein R4, R5, R6, and R7 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  本公开了化合物的结构式（I）和（Ia），或其药用盐、溶剂合物、互变异构体、立体异构体或重氘化类似物，其中R4、R5、R6和R7如本公开所述的各实施例中所述；其组合物；以及其用途。
• [EN] SUBSTITUTED CHROMAN-6-YLOXY-CYCLOALKANES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] CHROMAN-6-YLOXY-CYCLOALCANES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2014135674A1

  公开（公告）日：2014-09-12

  The present invention relates to substituted chroman-6-yloxy-cycloalkanes of the formula (I) in which Ar, R1 to R4, p and q are as defined in the claims. The compounds of the formula (I) are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula (I), their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式(I)的取代基氧基环己烷化合物，其中Ar、R1至R4、p和q如权利要求中所定义。式(I)的化合物是钠钙交换体抑制剂（NCX）, 特别是亚型1的钠钙交换体（NCX1）的抑制剂，适用于治疗细胞内钙离子平衡受到干扰的各种疾病，如心律失常、心力衰竭和中风。此外，本发明还涉及制备式(I)的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS
  申请人：CZECHTIZKY Werngard

  公开号：US20130065859A1

  公开（公告）日：2013-03-14

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及式I的取代2-(色甘醇-6-氧基)-噻唑衍生物，其中Ar、R2、R3和R4如权利要求中所定义。式I的化合物是钠-钙交换蛋白（NCX）的抑制剂，特别是亚型1的钠-钙交换蛋白（NCX1），适用于处理细胞内钙离子稳态受扰的各种疾病，如心律失常、心力衰竭和中风。本发明还涉及制备式I的化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。
• [EN] SUBSTITUTED 2-(CHROMAN-6-YLOXY)-THIAZOLES AND THEIR USE AS PHARMACEUTICALS<br/>[FR] 2-(CHROMAN-6-YLOXY)-THIAZOLES SUBSTITUÉS ET LEUR UTILISATION EN TANT QUE PRODUITS PHARMACEUTIQUES
  申请人：SANOFI SA

  公开号：WO2013037724A1

  公开（公告）日：2013-03-21

  The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1 ), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I中Ar、R2、R3和R4所定义的取代的2-(色甘醇-6-氧基)-噻唑。公式I的化合物是钠钙交换蛋白(NCX)的抑制剂，特别是亚型1的钠钙交换蛋白(NCX1)，适用于治疗细胞内钙稳态紊乱的各种疾病，如心律失常、心力衰竭和中风。此外，该发明还涉及制备公式I化合物的方法，它们作为药物的用途，以及包含它们的药物组合物。

表征谱图